Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in- human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, updated data demonstrates a further bacteria reduction of 2.7 log₁₀ (approximately 500-fold) compared to placebo, with no emergent resistance and preservation of a healthy microbiome About BX004 BiomX is advancing its Phase 2b trial of BX004 with topline results expected Q1 2026 NESS ZIONA, Israel, July 08, 2025 ( ...

Core Insights - BiomX Inc. is presenting positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO) at the Biomed Israel 2025 conference [1][2] - BX211 is a phage therapy targeting DFO associated with Staphylococcus aureus, a significant cause of amputation in diabetic patients [3][4] Presentation Details - The oral presentation titled "Precision Phage Therapy for Chronic Diabetic Foot Infections" will take place on May 21, 2025, from 12:15 to 2:15 pm IST at the InterContinental David Tel Aviv [2] - The session focuses on immunology and inflammation, highlighting opportunities in biopharma [2] BX211 Trial Results - The Phase 2 trial demonstrated that BX211 was safe and well-tolerated, with a statistically significant reduction in ulcer size (p = 0.046 at week 12; p = 0.052 at week 13) [3] - A separation from placebo was observed starting at week 7, with a difference greater than 40% by week 10 [3] - Statistically significant improvements were also noted in ulcer depth (p=0.048) and reduction of ulcer area expansion (p=0.017) [3] - The treatment period lasted 12 weeks, during which all patients received standard care, including systemic antibiotic therapy [3] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies for chronic diseases with unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]

BiomX (PHGE) Q1 2025 Earnings Call May 15, 2025 02:00 PM ET Speaker0 Greetings, and welcome to the BioMix First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to Marina Wolfson, Chief Financial Officer. Thank you. You may begin. Speaker1 Thank you, and welcome to the Bionics conference ca ...

Core Insights - BiomX announced positive topline results from the Phase 2 trial of BX211 for diabetic foot osteomyelitis, indicating significant progress in their clinical pipeline [1][2] - The company is preparing for a Phase 2/3 trial of BX211 pending FDA feedback and anticipates topline results for BX004 in cystic fibrosis in Q1 2026 [4][6] Clinical Program Updates - BX211 demonstrated safety and significant reduction in ulcer size with a p-value of 0.046 at week 12 and 0.052 at week 13, showing over 40% improvement by week 10 compared to placebo [3][12] - Statistically significant improvements were also observed in ulcer depth and area expansion, with p-values of 0.048 and 0.017 respectively [3][12] - The program has received approximately $40 million in non-dilutive funding from the U.S. Defense Health Agency to address antibiotic-resistant infections [2] Business Update - Shareholders approved the exercise of warrants related to $12 million in financing, providing operational runway into Q1 2026 [6] - The company’s cash balance increased to $21.2 million as of March 31, 2025, up from $18.0 million at the end of 2024, primarily due to recent financings [7] Financial Results - Research and development expenses rose to $5.3 million in Q1 2025 from $4.1 million in Q1 2024, driven by preparations for clinical trials [8] - General and administrative expenses decreased to $2.5 million in Q1 2025 from $2.7 million in Q1 2024 [9] - The net loss for Q1 2025 was $7.7 million, a significant reduction from $17.3 million in Q1 2024, attributed to changes in the fair value of warrants [10][25]

Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trialLOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat ...

BiomX (PHGE) Q4 2024 Earnings Call April 01, 2025 12:22 PM ET Company Participants Marina Wolfson - CFO & SecretaryJonathan Eitan Solomon - CEO and Board MemberJoe Pantginis - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech Analyst Operator Greetings, and welcome to today's BioMx Investor Presentation. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference ...

Core Viewpoint - BiomX Inc. announced positive topline safety and efficacy results from its Phase 2 trial of BX211, a phage therapy for diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus, indicating significant potential in addressing unmet medical needs in this area [1][2][3]. Summary of Phase 2 BX211 Results - The Phase 2 trial was a randomized, double-blind, placebo-controlled study involving 41 patients, with a treatment ratio of 2:1, where 26 received BX211 and 15 received placebo [4]. - BX211 was found to be safe and well-tolerated, showing a statistically significant reduction in ulcer size (Percent Area Reduction, PAR) with p-values of 0.046 at week 12 and 0.052 at week 13, with a notable separation from placebo starting at week 7 and a difference greater than 40% by week 10 [3][12]. - Statistically significant improvements were also observed in ulcer depth at week 13 (p=0.048) and in reducing the expansion of ulcer area (p=0.017) compared to placebo [12]. - The study demonstrated favorable trends across additional clinical parameters, including evidence of resolving DFO by MRI/X-ray and improvement in the Wagner scale [12]. Future Plans - Following the successful Phase 2 results, BiomX plans to initiate a Phase 2/3 trial of BX211, pending feedback from the U.S. Food and Drug Administration (FDA) [1][9]. - The company will present additional data from the Phase 2 study at upcoming scientific conferences [5]. Industry Context - The results highlight the therapeutic potential of phage therapy, particularly in treating infections where antibiotic resistance is a concern, addressing a significant unmet need in DFO, which currently leads to a high rate of lower extremity amputations [2][12]. - The company emphasizes the broader relevance of phage therapy in modern conflict scenarios and rising antibiotic-resistant infections, indicating a shift in treatment paradigms for chronic infections [2].